Market Summary

According to the current analysis of Emergen Research, the global Diabetic Ketoacidosis Market was valued at USD 1297.3 million in 2019 and is expected to reach USD 1973.6 million by 2027, at a CAGR of 6.2%. Increasing awareness among healthcare professionals about ketones build up during type 1 diabetes as well as type 2 diabetes, and favorable funding scenario for drug development and technological advancements in diabetes ketoacidosis treatment is anticipated to boost the growth of the market during the forecast period.

Furthermore, growing prevalence of type 1 diabetes across the globe, increasing availability of well-organized and technologically advanced diabetic ketoacidosis treatment in developing nations, significant R&D activities by the existing and emerging market players to develop effective drugs in an attempt to cater the demand supply gap in the market.

Some Key Highlights From the Report

• For diabetic ketoacidosis diagnosis, Beta-Hydroxybutyrate (BHB) assay remains a popular method to determine both the presence and degree of ketosis. Several market leaders are focused in expansion of BHB assay. For instance, Ortho Clinical Diagnostics and EKF Diagnostics announced to enter in an agreement to allow the Ortho Clinical Diagnostics clients to access Beta-Hydroxybutyrate (BHB) assay

• While hospitals segment dominates the end user segment of the market, it is anticipated that ambulatory care centers will register highest growth rate due to customised services provided to patients and growing awareness of such treatment centers in developed as well as developing nations.

• Development of advanced products for diabetic ketoacidosis management offers lucrative growth opportunities. There is a demand for products capable of significantly reducing diabetic ketoacidosis associated hospitalization rates and events of acute diabetes

Request Free Sample Copy@ https://www.emergenresearch.com/request-sample/73